Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immuneering Corporation - Class A Common Stock (NQ:IMRX)

5.750 +0.150 (+2.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 376,348
Open 5.620
Bid (Size) 5.670 (10)
Ask (Size) 5.740 (3)
Prev. Close 5.600
Today's Range 5.470 - 5.760
52wk Range 1.100 - 6.180
Shares Outstanding 25,938,064
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Immuneering Announces Closing of $25 Million Private Placement
From Immuneering Corporation
Via GlobeNewswire
Immuneering Inks Supply Agreement With Eli Lilly For Latter’s Investigational Cancer Therapy: Retail Looks To Buy The Stock On Dips
Via Stocktwits

Performance

YTD
+160.2%
+160.2%
1 Month
+58.4%
+58.4%
3 Month
+236.3%
+236.3%
6 Month
+248.5%
+248.5%
1 Year
+395.7%
+395.7%

More News

Read More
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
From Immuneering Corporation
Via GlobeNewswire
Top stock movements in today's session.
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Top movers analysis in the middle of the day on 2025-08-21: top gainers and losers in today's session.
Via Chartmill
There are notable gap-ups and gap-downs in today's session.
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Immuneering Announces $25 Million Private Placement
From Immuneering Corporation
Via GlobeNewswire
Immuneering Posts Narrower Loss in Q2
Via The Motley Fool
Topics Intellectual Property
Curious about the stocks that are showing activity after the closing bell on Wednesday?
Via Chartmill
Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib
From Immuneering Corporation
Via GlobeNewswire
Unusual volume stocks are being observed in Wednesday's session.
Via Chartmill
These stocks have an unusual volume in today's session
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Top movers in Wednesday's after hours session
Via Chartmill
Which stocks are experiencing notable movement on Wednesday?
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Here are the top movers in Wednesday's session.
Via Chartmill
Immuneering’s Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally
Via Stocktwits
These stocks are moving in today's session
Via Chartmill
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
From Immuneering Corporation
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
These stocks are gapping in today's session
Via Chartmill

Frequently Asked Questions

Is Immuneering Corporation - Class A Common Stock publicly traded?
Yes, Immuneering Corporation - Class A Common Stock is publicly traded.
What exchange does Immuneering Corporation - Class A Common Stock trade on?
Immuneering Corporation - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Immuneering Corporation - Class A Common Stock?
The ticker symbol for Immuneering Corporation - Class A Common Stock is IMRX on the Nasdaq Stock Market
What is the current price of Immuneering Corporation - Class A Common Stock?
The current price of Immuneering Corporation - Class A Common Stock is 5.750
When was Immuneering Corporation - Class A Common Stock last traded?
The last trade of Immuneering Corporation - Class A Common Stock was at 08/29/25 04:00 PM ET
What is the market capitalization of Immuneering Corporation - Class A Common Stock?
The market capitalization of Immuneering Corporation - Class A Common Stock is 149.14M
How many shares of Immuneering Corporation - Class A Common Stock are outstanding?
Immuneering Corporation - Class A Common Stock has 149M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.